Bernd Hohenstein

Albert Schweitzer Str. 6
Villingen-schwenningen, BW 78052, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

#CKDatWork: screening for CKD in occupational health.

#CKDatWork: screening for CKD in occupational health.

Journal: Clinical kidney journal

Published: May 05, 2026

Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.

Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.

Journal: Clinical kidney journal

Published: February 15, 2026

AI Application in Nephrological Diagnostics

AI Application in Nephrological Diagnostics

Journal: Deutsche medizinische Wochenschrift (1946)

Published: November 10, 2025

Lipoprotein apheresis in the era of new lipid-lowering therapies.

Lipoprotein apheresis in the era of new lipid-lowering therapies.

Journal: European heart journal

Published: October 16, 2025

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.

Journal: Acta cardiologica

Published: April 24, 2025

Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.

Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society

Published: April 08, 2025

First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.

First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.

Journal: Clinical kidney journal

Published: August 09, 2024

SGLT2-Inhibition in Patients With Alport Syndrome.

SGLT2-Inhibition in Patients With Alport Syndrome.

Journal: Kidney international reports

Published: July 23, 2024

The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.

The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.

Journal: Atherosclerosis

Published: March 23, 2024

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.

Journal: Cardiovascular drugs and therapy

Published: September 19, 2022

Post COVID and Apheresis - Where are we Standing?

Post COVID and Apheresis - Where are we Standing?

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Published: September 16, 2022

SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).

SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).

Journal: Infection

Published: November 20, 2021

Showing 1-12 of 72

Last Updated: 09/26/2026